Back to Search
Start Over
Morgan Stanley upgrades Jazz to Overweight on re-evaluation of Xyrem franchise
- Source :
- The Fly. August 6, 2020
- Publication Year :
- 2020
-
Abstract
- As previously reported, Morgan Stanley analyst David Risinger upgraded Jazz Pharmaceuticals to Overweight from Equal Weight with a price target of $177, up from $109. He has re-evaluated and significantly [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.631715548